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interruption strategy did not increase the costs related to adverse
events or consultations.
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OBJECTIVES: To analyze the cost-minimization of Daptomycin
in comparison to Vancomycin and Linezolid for patients with
Methicillin Resistant Staphylococcus Aureus (MRSA) skin and
soft tissues infections in Brazilian private payer perspective.
METHODS: The alternatives were indirectly compared due to
the absence of Head to Head studies. Resource consumption for
MRSA treatment were collected from previous publication and
divided into two categories: hospital care (including diagnostic
tests) and pharmaceuticals. Total treatment cost was investigated
for a base case where patients were treated in the best proﬁle
for each medicine effectiveness based on values extracted from
randomized open or blind studies [Daptomycin: Length of stay
(LOS) = 4 days with intravenous drug. Vancomycin: LOS = 7
days with intravenous drug. Linezolid: LOS = 4 days with intra-
venous drug and 11 days with oral drug]. The costs data regard-
ing medicines were collected from companies price list or price
submission process and utilization costs from literature. Results
were converted in US Dollars (R$ 1.7/USD 1.00). A one-way
sensitivity analysis was performed. RESULTS: For base case the
total treatment was US$1,646.89 for Daptomycin, US$1,843.84
for Vancomycin and US$3,290.46 for Linezolid. Pharmaceutical
inpatient cost was US$129.93 higher for Daptomycin in com-
parison with Linezolid and US$868,31 higher when compared
with generic-vancomycin; however this cost was offset by shorter
LOS. Despite the unitary prices of the Vancomycin and Linezolid
are lower than the price of Daptomycin, the total treatment costs
with Linezolid and generic-vancomycin is higher than with Dap-
tomycin. The sensitivity analysis on costs variables in an interval
of +/-20%, was robust with the base case. CONCLUSIONS: The
Daptomycin is a cost-saving alternative for MRSA skin and soft
tissues infections compared to generic-vancomycin and linezolid
in the perspective of Brazilian private payer.
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OBJECTIVES: Irrational antibiotic usage is still common in
Turkey and antibiotics are still the most commonly used drug in
Turkey. Our aim in this study was to evaluate the effects of
generic drug usage in inpatient clinics in Turkey, icompared to
brand names. METHODS: Data was collected from one univer-
sity hospital, internal medicine inpatient service for 1 month. A
total of 62 patients were treated with an antibiotic. The antibi-
otic’s name, dosage and the duration of use were recorded by
the nurses. The price of the antibiotics were extracted from the
Ministry of Health’s ofﬁcial price list. We compared the cost of
the bio-equivalent and the cheapest generic drugs with the origi-
nal drugs. RESULTS: During the month, the cost of the antibi-
otics used at the internal medicine inpatient clinic was €1136,
compared to the cheapst generics, which was €1013. In this
clinic, €2,2 per patient more was paid for the brand name anti-
biotics each month. If the 1400–1600 patients being treated with
antibiotic in this hospital per year are considered, an average of
€3300/month or €39,600/year is being paid for brand name
antibiotics. CONCLUSION: Considering antibiotics are the
most common used medication in Turkey (17% of total drug
usage), it can easily be understood how the use of Brand Name
drugs rather than Generics would lead to a vast economic
burden. This shows the importance of promoting the use of
generic antibiotics and the need for cost-minimalization analysis.
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OBJECTIVES: To estimate the cost and mortality impact of
stockpiling pre-pandemic inﬂuenza vaccine for Germany, from
a societal perspective. METHODS: A static decision analytic
model was developed to examine the balance between stockpil-
ing costs and potential cost-savings on primary care, medication,
hospitalization and productivity losses and to assess the number
of prevented deaths. The applied time horizon was ﬁve years. In
the base-case, the annual probability of a pandemic, the clinical
attack rate and case fatality rate in patients not receiving any
anti-viral medication were conservatively estimated at 3%, 30%
and 1%, respectively. The vaccine efﬁcacy was assumed to be
65%. The effect of anti-viral medication on costs and mortality
was considered. Stockpiling costs included acquisition, storage,
expected replacement and expected administration costs of the
vaccine. Productivity costs were estimated using the human
capital approach. All costs were expressed in €2008. Costs but
not deaths were discounted at 5% per year. Extensive univariate
and probabilistic sensitivity analyses were performed. RESULTS:
Stockpiling of pre-pandemic inﬂuenza vaccine was predicted to
cost €1.54 billion and avoid €7.48 billion direct and productivity
costs thus rendering net savings of €5.94 billion, (95% CI: €53
million; €16.3 billion). In addition, 17,711 deaths could be
avoided. The probability of stockpiling vaccine being cost-saving
was estimated at 97.7%. The most inﬂuential model parameters
were the annual risk of a pandemic, followed by the case fatality
rate. These results are likely to be conservative as herd immunity
and macroeconomic effects were not included. CONCLUSIONS:
Stockpiling of pre-pandemic vaccine can be considered a domi-
nant strategy for Germany as it is predicted to lead to cost-
savings and to avoid a considerable number of deaths.
PIN36
SOCIO-ECONOMIC IMPACT OF AVIAN INFLUENZA
IN SOUTH-EAST ASIA AND NEIGHBOURING HIGH
RISK COUNTRIES
Arora M, Srivastava K, Siddiqui MK,Verma J,Ahuja M, Sharma S
Heron Health Private Ltd, Chandigarh, India
OBJECTIVES: To review the socio-economic impact of avian
inﬂuenza in South-East Asian nations and neighbouring high risk
countries. METHODS: The information was retrieved from
the websites of World Bank, United Nations, clinicaltrials.gov,
Medline and relevant grey literature from 1995 to 2008. Only
English language articles and those covering South East Asia and
neighbouring nations were analysed. Number of cases of avian
inﬂuenza diagnosed, deaths in humans and poultry and associ-
ated socioeconomic impact were the outcomes of interest.
RESULTS: Of the 1973 citations, 134 met the inclusion criteria.
As per World Organisation for Animal Health, 6435 outbreaks
of avian inﬂuenza in poultry (4470 from South East Asia) have
been reported in 48 countries till June 2008. Fourteen countries
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